Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Debt to Equity: 2014-2021

Historic Debt to Equity for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Mar 2021 value amounting to $0.00.

  • Lineage Cell Therapeutics' Debt to Equity was N/A to $0.00 in Q1 2021 from the same period last year, while for Mar 2021 it was $0.00, marking a year-over-year change of. This contributed to the annual value of $0.01 for FY2020, which is N/A change from last year.
  • Lineage Cell Therapeutics' Debt to Equity amounted to $0.00 in Q1 2021, which was down 18.25% from $0.01 recorded in Q4 2020.
  • Lineage Cell Therapeutics' 5-year Debt to Equity high stood at $0.01 for Q3 2020, and its period low was $0.00 during Q4 2017.
  • For the 2-year period, Lineage Cell Therapeutics' Debt to Equity averaged around $0.01, with its median value being $0.01 (2020).
  • Data for Lineage Cell Therapeutics' Debt to Equity shows a maximum YoY crashed of 88.08% (in 2017) over the last 5 years.
  • Over the past 3 years, Lineage Cell Therapeutics' Debt to Equity (Quarterly) stood at $0.00 in 2017, then followed by $0.01 in 2020, then followed by $0.00 in 2021.
  • Its last three reported values are $0.00 in Q1 2021, $0.01 for Q4 2020, and $0.01 during Q3 2020.